48,310 Shares in Pfizer Inc. $PFE Acquired by Midway Capital Research & Management

Posted by Geri Gentry on Jun 20th, 2026

Midway Capital Research & Management acquired a new stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 48,310 shares of the biopharmaceutical company’s stock, valued at approximately $1,203,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Pfizer during the fourth quarter worth about $1,830,986,000. Morgan Stanley increased its holdings in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after acquiring an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after acquiring an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after acquiring an additional 7,489,189 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of PFE opened at $25.25 on Friday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $26.22 and its 200 day simple moving average is $26.33. The company has a market cap of $143.94 billion, a price-to-earnings ratio of 19.28 and a beta of 0.34. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is presently 131.30%.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Morgan Stanley boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, Citigroup upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.82.

Check Out Our Latest Stock Report on Pfizer

More Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.